Asset
Methotrexate
Aldeyra Therapeutics Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05392179 | phase2 | completed | 2022-07-14 | 2023-06-23 | Aldeyra Therapeutics, Inc. | A Study in Subjects With Retinitis Pigmentosa |
| NCT04136366 | phase3 | completed | 2019-11-15 | 2022-06-14 | Aldeyra Therapeutics, Inc. | The GUARD Trial - Part 1: A Phase 3 Clinical Trial for Prevention of Proliferative Vitreoretinopathy |
FDA applications (0)
This company has no applications containing this asset.